KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Laparoscopic Pylorus-preserving Gastrectomy Versus Distal Gastrectomy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial (KLASS-04). PMID 39219553 · Ann Surg · 2025-Apr-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Thoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial. PMID 38335141 · Anesth Analg · 2025-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Psycho-oncology/Supportive Care in Head-Neck Cancers Patients Undergoing Radiation Therapy: A Randomized Controlled Trial. PMID 41426184 · South Asian J Cancer · 2025-Apr The trial is a randomized controlled trial in human oncology patients, but it does not meet the primary eligibility criteria. The intervention is psycho-oncology/palliative/supportive care referral (non-drug), and the primary endpoint is distress proportion (not a time-to-event endpoint like OS/PFS/DFS). Although survival endpoints are mentioned as having no significant difference, the report does not focus on or provide data for a primary/key secondary time-to-event efficacy endpoint suitable for Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Clinical efficacy of endocrinotherapy combined with Shenqi Pills on patients with hormone-sensitive prostate cancer]. PMID 40787962 · Zhonghua Nan Ke Xue · 2025-Apr The study is a randomized oncology trial in humans with a primary OS endpoint, but it is ineligible because the intervention combines a standard drug therapy with a Chinese herbal product (Shenqi Pills), which does not meet the strict 'drug-containing intervention' criterion for conventional drugs. Additionally, the trial phase is not explicitly reported as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Clinical efficacy of prostatectomy combined with neoadjuvant endocrine therapy]. PMID 40787958 · Zhonghua Nan Ke Xue · 2025-Apr The record describes a randomized controlled trial in oncology (prostate cancer) with a drug-containing intervention (neoadjuvant endocrine therapy). However, it does not report a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, event-free survival, recurrence-free survival, time to progression, or any Kaplan-Meier or hazard ratio analysis. The outcomes reported are clinical indicators, immune function, serum markers, complications, and a non-formal one-year recurrence rate. Therefore, it does not meet the eligibility requirement for a time-to-event efficacy endpoint. The phase is not explicitly stated, so phase3_or_definitive is null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Metformin for recurrent colorectal polyp or adenoma prevention after polypectomy in patients without diabetes mellitus: a prospective study. PMID 40353629 · Neoplasma · 2025-Apr The study is a randomized, oncology, human, drug-intervention trial with original results, but it is excluded because the primary endpoint is not a time-to-event outcome (it is a binary proportion of adenoma recurrence at 1 year). There is no signal for OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. PMID 40337868 · Immunotherapy · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of colonoscopy screening on risks of colorectal cancer and related death: instrumental variable estimation of per-protocol effects. PMID 40278966 · Eur J Epidemiol · 2025-Apr The study is an oncology randomized trial (NordICC) evaluating colonoscopy screening for colorectal cancer prevention, with cancer incidence and mortality as primary endpoints. While it meets criteria for being oncology, human, randomized, and an original result, it does not contain a drug intervention (colonoscopy is a procedural/screening intervention, not a drug). Therefore, it fails the drug-intervention criterion and is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy. PMID 40268743 · Cancer Invest · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer in Egypt. PMID 40267379 · JCO Glob Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Three-field vs two-field lymphadenectomy in thoracic ESCC patients: a multicenter randomized study (NST 1503). PMID 40265094 · J Natl Cancer Cent · 2025-Apr The study is an oncology randomized trial with time-to-event endpoints (OS, DFS) and reports original results. However, the intervention is purely surgical (lymphadenectomy techniques) and does not involve a drug-containing intervention, which is a required criterion for eligibility. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata or abstract text.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma. PMID 40264918 · JCO Oncol Adv · 2025-Apr Record fails required criteria due to missing abstract content, which prevents verification of human subjects and the presence of a time-to-event efficacy endpoint. The title suggests eligibility, but without an abstract, we cannot confirm the report contains original results or that a time-to-event endpoint is reported.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial. PMID 40247887 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. PMID 40242562 · EClinicalMedicine · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. PMID 40241307 · Eur J Neurol · 2025-Apr 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial. PMID 40230305 · Health Technol Assess · 2025-Apr The record is a prospective prognostic model study in colorectal cancer, not a randomized drug intervention trial. It is an observational cohort evaluating biomarkers and imaging for prognosis, lacking randomization, a drug intervention, and a therapeutic efficacy endpoint. The deterministic review correctly flagged unclear Phase III evidence, and deeper analysis confirms ineligibility based on core criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Symptom Attribution, Help Seeking and Willingness to Undergo Diagnostic Investigations for Bowel Cancer Symptoms in People With Anxiety and/or Depression-A Vignette Study. PMID 40220329 · Psychooncology · 2025-Apr The study is a randomized vignette study investigating symptom attribution, help-seeking, and willingness to undergo diagnostic tests for bowel cancer symptoms in people with anxiety/depression. It is an oncology-related human study but lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). It is not a Phase III/IIIb or Phase II/III drug efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. PMID 40209141 · JCO Precis Oncol · 2025-Apr The report is a secondary, retrospective biomarker subgroup analysis of the PENELOPE-B trial, not the original primary result report of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis. PMID 40204996 · Nat Cancer · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Combined Treatment With Cognitive Behavioral Therapy for Insomnia and Acceptance and Commitment Therapy Enhances Objective and Subjective Reports of Sleep in Patients With Advanced Cancer. PMID 40204663 · Psychooncology · 2025-Apr The study is an oncology, human, randomized trial with original results, but it is not a Phase III/IIIb or Phase II/III drug intervention trial (it is a non-drug cognitive-behavioral therapy pilot study) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Controlled 'REAL-FITNESS' Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma. PMID 40196920 · J Cachexia Sarcopenia Muscle · 2025-Apr The trial is a randomized, oncology study with human patients and reports original results including a time-to-event endpoint (event-free survival). However, it is not eligible because the intervention is primarily exercise/physical activity, not a drug-containing intervention. The study evaluates exercise during standard drug therapy (VCd), but the drug regimen is the control/background therapy, not the experimental intervention. The phase of the trial is not explicitly stated as Phase III or definitive in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Storytelling Through Music With Parents Whose Children Have Died From Cancer: A Randomized Controlled Feasibility Trial. PMID 40195024 · Psychooncology · 2025-Apr The study is a randomized feasibility trial of a psychosocial bereavement intervention for parents of children who died from cancer. It is not a drug intervention trial, does not evaluate a cancer therapeutic, and does not use time-to-event efficacy endpoints (OS, PFS, etc.) or Kaplan-Meier/HR analyses.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial. PMID 40180472 · Lancet HIV · 2025-Apr The study is a randomized, placebo-controlled Phase III trial (REPRIEVE) with drug intervention and time-to-event endpoints, but it is not an oncology trial. Its primary focus is cardiovascular disease prevention in people with HIV. The cancer-related endpoint (non-AIDS-defining cancer) is only a component of a composite secondary endpoint (START outcome), not the primary or key secondary efficacy endpoint for an oncology indication. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort requiring a trial for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. PMID 40175001 · Lancet Haematol · 2025-Apr The trial is a randomized, open-label study in human oncology (chronic lymphocytic leukaemia) with a drug intervention (BTK inhibitors). However, it is a Phase II trial (not Phase III/IIIb or Phase II/III as defined) and the primary efficacy endpoint is immunogenicity (anti-spike antibody titre), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Low-Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double-Blind Randomized Clinical Trial. PMID 40152076 · Cancer Med · 2025-Apr Study is a randomized, double-blind, drug-intervention (fluconazole) trial in acute leukemia (oncology/human) reporting original results. However, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier analysis or hazard ratio. Outcomes focus on infection incidence, colonization, and adverse events, not time-to-event survival.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. PMID 40147459 · Lancet Oncol · 2025-Apr The trial is ineligible because it does not have a drug-containing intervention and does not have a primary or key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up). PMID 40147400 · Lung Cancer · 2025-Apr The study is a randomized, multi-center, non-inferiority trial in oncology with human subjects and time-to-event endpoints (OS, DFS). However, it does not involve a drug-containing intervention; it compares diagnostic/surgical strategies (endosonography with or without confirmatory mediastinoscopy). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. PMID 40140623 · Nat Med · 2025-Apr Eligibility cannot be determined because the record is a published erratum (correction) for a trial, not the original result report itself. The provided metadata lacks an abstract or any content describing study outcomes, making it impossible to confirm the presence of a primary/key secondary time-to-event efficacy endpoint, which is a required criterion for inclusion. Metadata does not establish human subject participation.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. PMID 40139026 · Gynecol Oncol · 2025-Apr The record is an original result report from the ENGOT-OV16/NOVA Phase III randomized trial evaluating niraparib maintenance therapy in recurrent ovarian cancer. It explicitly reports survival (OS) and other time-to-event efficacy endpoints with hazard ratios, meets all eligibility criteria (oncology, human, randomized, phase 3, time-to-event, drug intervention, original result), and is not a subgroup, safety-only, or secondary analysis report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Managing Cancer and Living Meaningfully in adults with brain metastases: A NIH ORBIT model phase II feasibility and proof-of-concept trial. PMID 40110068 · Neurooncol Pract · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Comparitive Study Between Early Outcomes of Laser and Lay-Open Technique in Management of Simple Pilonidal Sinus. PMID 40108765 · Lasers Surg Med · 2025-Apr 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial. PMID 40098532 · Future Oncol · 2025-Apr The record is a protocol for a randomized, pragmatic clinical trial evaluating a conversation tool for shared decision-making in lung cancer. It is oncologic and human, but lacks explicit Phase III designation, does not involve a drug intervention, and has no time-to-event efficacy endpoint (primary outcomes are decisional conflict, self-efficacy, communication satisfaction, and knowledge). It is a protocol, not a results report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial. PMID 40071721 · J Dermatol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open parenchymal preserving liver resections in the posterosuperior segments (ORANGE Segments): a multicentre, single-blind, randomised controlled trial. PMID 40060302 · Lancet Reg Health Eur · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. PMID 40051275 · Future Oncol · 2025-Apr 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials. PMID 40037029 · Clin Genitourin Cancer · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. PMID 40023017 · Lung Cancer · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Postoperative changes in body composition after laparoscopic and open resection of colorectal liver metastases: data from the randomized OSLO-COMET trial. PMID 39994051 · Surg Endosc · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effectiveness of Breast Density Educational Interventions on Mammography Screening Adherence Among Underserved Latinas: A Randomized Controlled Trial. PMID 39969957 · J Womens Health (Larchmt) · 2025-Apr The study is a randomized controlled trial with a primary time-to-event efficacy endpoint (Kaplan-Meier, HR) and is an original result. However, it is excluded because it does not involve a drug-containing intervention; the interventions are educational/informational (brochures, letters).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eligibility for donanemab trial in a population-based study of cognitive aging. PMID 39966022 · J Prev Alzheimers Dis · 2025-Apr The record describes a population-based study assessing eligibility criteria for a Phase III donanemab trial in Alzheimer's disease. It is not an oncology trial, does not report randomized trial results, and lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma. PMID 39955187 · Int J Gynecol Cancer · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. PMID 39948407 · Nat Med · 2025-Apr The record is a published erratum/correction for a phase 3 trial (CEPHEUS). While the underlying trial meets the oncology, phase 3, randomized, and drug intervention criteria, the provided record is not an original result report and lacks any explicit time-to-event efficacy endpoint data. Therefore, eligibility cannot be confirmed, and it is excluded.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. PMID 39920394 · Nat Med · 2025-Apr The trial is a cluster-randomized trial in oncology with a primary OS endpoint, but the intervention is non-drug (electronic symptom monitoring).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. PMID 39914435 · Lancet Gastroenterol Hepatol · 2025-Apr The study is a randomized controlled trial with a drug intervention and a time-to-event primary endpoint, but it is not an oncology trial. The disease is chronic hepatitis B, and the primary endpoint is the prevention of liver-related serious adverse events (including hepatocellular carcinoma as a component), not the treatment of an existing malignancy. Therefore, it does not meet the required oncology criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol. PMID 39909737 · J Geriatr Oncol · 2025-Apr 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Standard Versus Reduced Hydration to Improve Elimination of High-Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial. PMID 39868759 · Pediatr Blood Cancer · 2025-Apr Study is an oncology RCT with drug intervention (methotrexate) and original results, but it is a Phase II/pilot study (not Phase III/IIIb), and its primary endpoint is time to drug elimination (pharmacokinetic), not a survival or disease progression time-to-event efficacy endpoint (OS, PFS, DFS, etc.). No Kaplan-Meier curves or hazard ratios are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fiber, lactose and fat-modified diet for the prevention of gastrointestinal chemo-radiotherapy-induced toxicity in patients with cervical cancer: Randomized clinical trial. PMID 39848009 · Nutrition · 2025-Apr The study is an oncology RCT with a time-to-event endpoint, but the intervention is dietary (fiber, lactose, fat modification) and not a drug. Phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431). PMID 39847268 · Qual Life Res · 2025-Apr The record describes a psychometric analysis of a patient-reported outcome questionnaire from a Phase 3 randomized trial, but it does not report any primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results, and it does not explicitly specify a drug intervention. Therefore, it does not meet the eligibility criteria for a drug-intervention oncology trial with time-to-event efficacy.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prolonged vs standard thromboprophylaxis in patients with esophageal cancer undergoing surgery: a randomized controlled study. PMID 39842514 · J Thromb Haemost · 2025-Apr While the record is an original randomized controlled trial in oncology with a drug intervention (low-molecular-weight heparin), it does not meet the core requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary endpoint was a biomarker (F1+2), and the secondary outcomes (venous thrombosis incidence, mortality) are not presented as time-to-event analyses with KM or HR. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis. PMID 39841181 · Eur J Clin Pharmacol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -